To examine the association between vascular pathology and rate of cognitive decline in older adults independent of Alzheimer's disease (AD) pathology. DESIGN: Prospective cohort study. SETTING: Community sample. PARTICIPANTS: Individuals from the Einstein Aging Study autopsy series (N = 62).
A lthough the clinical syndromes of vascular dementia and Alzheimer's disease (AD) were previously considered to be the result of independent processes, it is now recognized that vascular disease and vascular risk factors may contribute to dementia regardless of subtype. [1] [2] [3] Recent community-based neuropathological studies have revealed that AD and vascular pathologies frequently occur in the same individuals and that the most-common etiology of dementia in elderly adults is mixed vascular and AD pathology. 4, 5 The functional and pathogenic synergy between neurons, glia, and vascular cells suggested in prior studies [6] [7] [8] provide a framework to evaluate how cerebrovascular disease might contribute to the neuronal dysfunction underlying cognitive impairment.
Data from imaging and clinical-neuropathological correlation studies have suggested that vascular pathology exacerbates the clinical presentation of AD and increases the risk of clinically evident cognitive impairment, 9, 10 but the extent to which vascular pathology contributes to cognitive decline independent of AD pathology has not been well established in a community-based autopsy series. Better understanding the relationship between vascular pathology and cognitive decline would enhance the ability to develop strategies for prevention or slowing of cognitive decline and progress to dementia.
The Einstein Aging Study (EAS) autopsy series provides the opportunity to explore the association between vascular lesions and antemortem cognitive decline and to test whether this association is independent of AD pathology. Development of a summary vascular score to quantify macrovascular lesions (MVLs) has been described, and it has been found that greater vascular burden is associated with greater probability of an antemortem diagnosis of clinical dementia. 11 The aim of current study was to examine whether vascular lesion burden is independently associated with antemortem rate of cognitive decline after adjusting for level of AD pathology.
METHODS

Study Population
The analysis included individuals enrolled in an EAS autopsy study. Of the 86 EAS autopsy cases who had completed an antemortem neuropsychological battery since 1993, the analysis excluded those with dementia at study baseline (n = 14) and those with more than 5 years between last study visit and time of death (n = 10). The final analysis sample comprised 62 subjects. Methods of recruitment, subject examination, determination of cognitive status, and exclusion criteria from the overall cohort have been described previously. 11, 12 Written informed consent for clinical evaluation and the autopsy program was obtained from all subjects and surrogate decision-makers at enrollment using protocols that the local institutional review board had approved.
Cognitive Assessment
Subjects underwent clinical and neuropsychological evaluations at enrollment and every 12 to 18 months. Board-certified neurologists with expertise in geriatric neurology performed clinical evaluations. All participants completed a standardized neuropsychological battery validated for use in normal aging populations. 13 The BIMC, which has high test-retest reliability (0.86) and correlates well with AD pathology, was used to screen for global cognitive status. 14, 15 Dementia was diagnosed according to case conference consensus using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised. 16, 17 The study neurologists, a licensed neuropsychologist, and a study social worker reviewed all available clinical and neuropsychological data. Participants with dementia at enrollment were excluded for the purposes of this analysis.
Neuropathology
A single experienced neuropathologist, (D.W.D.) blinded to clinical status, provided neuropathological evaluations. Details of brain autopsy and pathological processing has been described in detail. 11 All cases were assigned a Braak neurofibrillary tangle (NFT) stage 18 based upon the distribution of NFTs on thioflavin-S sections. For analysis, Braak NFT stage was dichotomized as low (<3) or high (≥3).
Ischemic vascular lesions were identified according to macroscopic examination of 0.5-cm-thick coronal sections of cerebral hemispheres and transverse sections of brainstem and cerebellum. The three types of MVLs used for the purpose of this study were ischemic vascular lesions (large infarcts and lacunar infarcts) and leukoencephalopathy. Circumscribed areas of softening (encephalomalacia), whether cystic or partially cystic, with maximum diameter >1 cm were classified as large infarcts. Lacunar infarcts were defined as cystic lesions < 1 cm in diameter. Lacunar infarcts, which correlate with the presence of small vessel arteriosclerotic vascular disease, were most often found in the basal ganglia, thalamus, pontine base, and periventricular white matter. Leukoencephalopathy was assessed based on the presence of rarefaction of the white matter, dilation of perivascular spaces in the white matter, and presence of reactive astrocytes and less often macrophages. Acute and subacute infarcts, lacunes, microinfarcts, or hemorrhages near the time of death were noted but not included in the vascular scores or analyses. The decision to exclude was based upon the histological appearance of the lesions and presence of acute neuronal necrosis and neutrophils.
Vascular Score
To understand the clinical relevance of the findings and to study the effect of cumulative vascular burden irrespective of type of vascular lesion, similar to a previous study, 11 a summary pathological vascular lesion score based on presence and number of the three types of MVLs (large infarct, lacunar infarct, leukoencephalopathy) associated with neuroimaging correlates during life was used. Details of the score are presented in Table S1 . MVLs were studied as a categorical variable (0, 1 or 2, ≥3) to look for a possible threshold effect of vascular burden on cognitive impairment.
Data Analysis
Clinical characteristics were summarized using descriptive statistics, and comparisons between levels of MVLs used analyses of variance for continuous variables and chisquare tests for categorical variables.
Linear mixed-effect models were used to assess the association between vascular and AD pathology and the trajectory of cognitive function before death, with BIMC score modeled as a function of time in years since enrollment, age at enrollment, sex, years of education, and presence of vascular or AD pathology. A random intercept and random slope were used to account for within-person variation. Robust empirical estimates of standard errors were used to take into account the skewed distribution in BIMC score. 19 The association between MVL and Braak stage and cognitive decline were evaluated separately and jointly. Possible interactions between MVL score and Braak stage were evaluated by including an interaction term between MVL and Braak stage and time and by examining the association between MVL and cognitive trajectory within each Braak stage group separately.
A priori level of statistical significance was set at .05. Programming was performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Study Population and Neuropathology Characteristics
Sample characteristics are summarized in Table 1 . Mean age was 81.8 AE 6.2 at enrollment and 89.0 AE 6.9 at death; 33 (53.2%) of participants were female; 56 (90.3%) were white, five (8.1%) were black, and one was Hispanic. Twenty-three participants met clinical criteria for dementia at their last clinical evaluation, including 12 with probable or possible AD, six with vascular dementia (VaD), and three with mixed AD and VaD (Chui et al., 1992) . The median interval between the last clinical evaluation and death was 1.28 years (range 0.03-4.76 years).
Brain Pathology and Cognitive Decline
Estimates of the association between vascular and AD pathology and annual rate of change in BIMC score are summarized in Table 2 . Models 1 and 2 are for the evaluation of MVL and Braak stage in separate models, respectively. Participants with more than two MVLs had faster cognitive decline than those with no MVLs (difference in annual rate of change in BIMC 0.74 points/yr; P = .03). The rate of global cognitive decline in participants with one or two MVLs was slightly faster than but not significantly different from the rate of decline in those with no vascular lesions. Mean trajectories of BIMC score for each MVL level are shown in Figure 1 . Model 2 indicated that higher Braak stage (≥3 vs <3) was associated with faster cognitive decline (difference in annual rate of decline in BIMC 0.57 points/yr, P = .003). Model 3 included MVL and Braak stage to assess whether the effect of vascular pathology is independent of AD pathology. The difference in the rate of cognitive decline in BIMC between those with an MVL score of 3 or greater and those without vascular lesion persisted after adjustment for AD pathology (difference in rate of change in BIMC 0.68 points/yr, P = .04). Given the significantly longer time between death and last cognitive examination for individuals with the greatest vascular burden, the analysis was rerun after adjusting for time between last testing and death; this adjustment did not make difference in the final outcomes (results not shown).
Interaction Between Alzheimer's and Vascular Pathology
There was no significant interaction between MVL and Braak stage on rate of general cognitive decline (P = .77), indicating that AD pathology did not modify the association between vascular pathology and cognitive decline.
DISCUSSION
This community-based clinical-pathological study showed that MVLs and AD pathology are associated with the rate of global cognitive decline. Furthermore, the effect of macrovascular brain pathology on cognitive decline persisted after adjustment for level of AD pathology.
The observation that vascular pathology is associated with rate of cognitive decline independent of AD pathology is consistent with results of other prospective autopsy series. [20] [21] [22] In the Religious Orders Study, the likelihood of dementia was greater with greater AD pathology and more macroscopic infarcts. 20 The same group has also reported that microinfarcts, particularly multiple cortical microinfarcts, increased the odds of dementia independent of AD pathology. 10 In the Honolulu Asia Aging Study, AD and microinfarcts contributed independently to dementia risk, 21 and another study 22 also reported that cerebrovascular disease, AD, and hippocampal sclerosis each contributed independently to cognitive status. Although the relationship between vascular lesions and cognitive decline was defined qualitatively in these studies (multiple lesions having a greater effect than no lesions or a single lesion), results from Baltimore Longitudinal Study of Aging 23 showed that there is a direct relationship between number of macroscopic infarcts and odds of dementia. In line with the latter study, the current study results indicated that having more MVLs (>2) was associated with cognitive decline independent of AD pathology.
An important question is how vascular and AD pathologies combine to cause cognitive decline. Prior clinical-pathological studies did not yield consistent results regarding an interaction between vascular and AD pathologies in relation to clinical cognitive performance. The Nun Study 24 found that cerebral infarction significantly increased the likelihood of dementia only in individuals with higher levels of AD pathology, but other studies such as the Baltimore Longitudinal Study of Aging, 23 the Religious Orders Study, 25 and the Medical Research Council Cognitive Function and Aging Study 26 did not find evidence that the effect of vascular pathology depended upon the extent of AD pathology with respect to cognitive function. The current data also suggest that the effect of macrovascular brain pathology on cognitive function is uniform in groups with low or high burden of AD pathology. The disparities between prior studies might be due to differences between sample types (community vs clinical cohorts), 27 use of different pathological criteria (subcortical vs cortical vascular lesions), 23 or limitations of small sample size for detecting differences. These incongruent results indicate that further work in larger communitybased samples is required to clarify the interaction between vascular and AD pathology in relation to cognitive performance.
The current study supports that addressing vascular risk factors may help prevent or delay cognitive decline. AD and cerebrovascular disease share common risk factors, including hypertension, hyperlipidemia, diabetes mellitus, insulin resistance, obesity, and hyperhomocystinemia, 28, 29 which are all potentially modifiable. Regardless of whether AD and vascular pathologies are additive or synergistic, these findings add to the growing body of evidence suggesting that strategies to address these risk factors may reduce the risk of cognitive decline or slow the onset of clinical dementia.
The strengths of this study include the detailed assessment of clinical and neuropathological data by experienced examiners and use of validated diagnostic procedures. Although the findings are promising, a few limitations should be noted. First, the temporal sequence of the pathologies before death was unknown, because this was a clinical-pathological correlation study. Thus, it was not possible to assess the concurrent associations between pathology and cognitive performance during antemortem follow-up. Second, neuropathological evaluations were performed on one hemisphere. Third, identification of vascular pathology was based on gross brain sections, which is likely to have resulted in underestimation of the association between vascular lesions and clinical diagnosis of dementia. Use of techniques such as myelin staining of brain sections would improve quantification of white matter pathology, but these techniques may not have clinical or imaging correlates. In this study, the primary focus was on MVLs and Braak staging as measures of vascular burden and AD, but other measures such microscopic vascular lesions and senile plaque burden might also play a significant role in the observed interactions. Therefore, further studies are required to clarify the role of and interactions between other types of pathological lesions in cognitive decline. Finally, the sample size was small and therefore might have been underpowered to detect interactions between vascular burden and NFT pathology. This small sample size also makes comparison between subgroups of dementia types difficult.
CONCLUSIONS
In summary, vascular pathology, a common neuropathological finding in older adults, increases the rate of cognitive decline independent of AD pathology. The effect of macrovascular brain pathology on cognitive function is uniform in groups with low and high burden of AD pathology.
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